Search Results for: Immunosuppressants

July 6, 2019July 6, 2019

TNF-Alpha Inhibition and Other Immunosuppressants in the Development of Uveal and Cutaneous Melanoma.

Melanoma Literature

Publication date: Jul 01, 2019 To investigate an association between tumor necrosis factors-alpha (TNFα) inhibitors or other immunosuppressants and the development of uveal and cutaneous melanoma. We performed a retrospective ... Read more

July 2, 2019July 2, 2019

Immunosuppressants in the Development of Melanoma

Melanoma Media

Publication date: Jul 01, 2019 Dr. Lauren A. Dalvin, Director of the Ocular Oncology Service at Mayo Clinic in Rochester, MN, reviews her article appearing in the July 2019 issue ... Read more

February 21, 2018February 21, 2018

Investigational immunosuppressants in early stage clinical trials for the treatment of multiple sclerosis.

Multiple Sclerosis Literature

Publication date: Feb 19, 2018 Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system with an immune mediated pathogenesis. Several therapies that suppress or modulate diverse ... Read more

August 13, 2019August 13, 2019

Regulation of Lipid Metabolism in Autoimmune Disease: Multiple Sclerosis

Multiple Sclerosis News

Publication date: Aug 12, 2019 The aim of this research is to understand how lipids such as cholesterol affect the disease process in people with MS. Concepts Keywords Alemtuzumab Conduct ... Read more

August 8, 2019August 8, 2019

A Pilot Study to Characterize the Biological Effect of a Pre-planned 12 Week Dose Interruption of Natalizumab

Multiple Sclerosis News

Publication date: Aug 07, 2019 This is an open-label study of patients with relapsing forms of MS is designed to assess the biochemical, immunological, and kinetic profiles of natalizumab being ... Read more

July 31, 2019July 31, 2019

Ponesimod Fares Well in Phase 3 Trial for Relapsing MS, Janssen Announces

Multiple Sclerosis News

Publication date: Jul 30, 2019 Janssen has announced positive, top-line results from its Phase 3 OPTIMUM study, testing the effectiveness and safety of ponesimod tablets, compared to Sanofi’s Aubagio (teriflunomide), ... Read more

July 30, 2019July 30, 2019

A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis

Multiple Sclerosis News

Publication date: Jul 29, 2019 This study will evaluate the efficacy and safety of ocrelizumab ( Ocrevus(R)) compared with placebo in participants with primary progressive multiple sclerosis (PPMS), including participants ... Read more

July 30, 2019July 30, 2019

Early Gilenya Treatment Lessens Disability Progression and Disease Activity in Young RRMS Patients, Study Shows

Multiple Sclerosis News

Publication date: Jul 29, 2019 Early and continuous treatment with Gilenya (fingolimod) in young people – those ages 30 years or younger – with relapsing-remitting multiple sclerosis (RRMS) decreases the ... Read more

July 30, 2019July 30, 2019

EMA alerts women not to use multiple sclerosis medicine, Gilenya during pregnancy

Multiple Sclerosis News

Publication date: Jul 30, 2019 The European Medicines Agency (EMA) has recommended that the multiple sclerosis medicine Gilenya (fingolimod) must not be used in pregnant women and in women able ... Read more

July 28, 2019July 28, 2019

Tacrolimus exposure after liver transplantation for alcohol-related liver disease: Impact on complications.

Melanoma Literature

Publication date: Jul 24, 2019 Alcohol-related liver disease (ALD) is one of the main indications for liver transplantation (LT). For 20 years, tacrolimus (Tac) is the cornerstone immunosuppressive drug used after ... Read more